How should I manage a patient with serum creatinine 1.55 mg/dL (creatinine‑based eGFR ≈48 mL/min/1.73 m²), cystatin C 1.3 mg/L (cystatin C‑based eGFR ≈53 mL/min/1.73 m²), and BMI 37 (class II obesity)?

Management of CKD Stage G3a with Class II Obesity

In this patient with eGFR 48–53 mL/min/1.73 m² and BMI 37, initiate an SGLT2 inhibitor immediately (regardless of diabetes status or albuminuria level), as this represents the strongest evidence-based intervention to reduce kidney disease progression and cardiovascular mortality 1.

Critical First Step: Obtain Urine Albumin-to-Creatinine Ratio

You cannot fully risk-stratify or optimize therapy without knowing the albuminuria status. Order a spot urine ACR immediately—this single test will determine whether you add 1,2, or 3 kidney-protective medications.

Interpreting the eGFR Discrepancy in Obesity

Your patient shows a 5 mL/min difference between creatinine-based (48) and cystatin C-based (53) eGFR. In class II obesity (BMI 37), creatinine-based equations systematically underestimate true GFR while cystatin C equations may overestimate it 2, 3, 4. The most recent high-quality evidence demonstrates that combined creatinine-cystatin C equations (eGFRcr-cys) outperform either marker alone across the entire BMI spectrum 2.

• For clinical decision-making in this patient, use eGFRcr-cys ≈ 50 mL/min/1.73 m² as your working estimate
• This places the patient solidly in CKD Stage G3a
• The obesity itself increases cystatin C independent of kidney function 4, 5, so the cystatin C-only estimate of 53 may be falsely reassuring

Medication Algorithm Based on Albuminuria Status

If ACR ≥200 mg/g (≥20 mg/mmol):

1. SGLT2 inhibitor (1A recommendation) 1

   • Start dapagliflozin 10 mg daily, empagliflozin 10 mg daily, or canagliflozin 100 mg daily
   • Safe to initiate at eGFR ≥20 mL/min/1.73 m²
   • Continue even if eGFR drops below 20 unless dialysis starts
   • Expect a reversible 3–5 mL/min eGFR dip in first 2–4 weeks—this is hemodynamic, not nephrotoxic, and does not require discontinuation 1

2. ACE inhibitor or ARB (1B recommendation for diabetes; 1B for non-diabetes with A3 albuminuria) 1, 6

   • Titrate to maximum approved dose (e.g., lisinopril 40 mg daily, losartan 100 mg daily)
   • Check creatinine, potassium, and BP at 2–4 weeks
   • Continue unless creatinine rises >30% within 4 weeks or uncontrolled hyperkalemia develops 1, 6
   • Do not stop when eGFR falls below 30—continue through Stage G4 1

3. If diabetes present AND albuminuria persists despite RASi + SGLT2i: Add nonsteroidal MRA (finerenone) if potassium ≤4.8 mmol/L and eGFR >25 mL/min/1.73 m² (2A recommendation) 1, 6

   • Start finerenone 10 mg daily (eGFR 25–59)
   • Recheck potassium in 4 weeks, then every 4 months
   • Hold if K⁺ >5.5 mmol/L; adjust diet/medications and retry when normalized 1

If ACR <200 mg/g (<20 mg/mmol):

1. SGLT2 inhibitor (2B recommendation for eGFR 20–45 with low albuminuria) 1, 6

   • Same dosing as above
   • Weaker evidence base but still recommended given eGFR 48–53 range

2. Consider RASi only if:

   • Hypertension requiring treatment (target BP <120/80 if tolerated) 6
   • Heart failure with reduced ejection fraction 1
   • Diabetes with A2 albuminuria (30–200 mg/g) 1, 6

If Heart Failure Present (Any Albuminuria Level):

SGLT2 inhibitor becomes 1A recommendation regardless of albuminuria 1, 6. This is a critical distinction—heart failure elevates SGLT2i to the highest evidence tier even without significant kidney disease markers.

Obesity-Specific Considerations

The BMI 37 matters for three reasons:

1. Drug dosing: If this patient requires renally cleared narrow-therapeutic-index drugs (vancomycin, aminoglycosides, DOACs), use adjusted body weight or lean body weight formulas, not total body weight in Cockcroft-Gault 7. Total body weight overestimates clearance by 19–34% in class II obesity, leading to supratherapeutic levels and toxicity.

2. Weight loss: Every 1 kg/m² reduction in BMI improves kidney outcomes. Refer for structured weight management; consider GLP-1 receptor agonists (semaglutide, tirzepatide) which provide dual cardiorenal and weight benefits.

3. Monitoring frequency: Obesity increases insulin resistance and metabolic syndrome risk 5. Check HbA1c, lipids, and liver enzymes if not recently done—these often coexist and require treatment.

Monitoring Protocol

• Weeks 2–4 after starting RASi or SGLT2i: Creatinine, potassium, BP
• Every 3–6 months: eGFR, ACR, potassium, BP
• Annually: HbA1c (if diabetic or prediabetic), lipids, hemoglobin (screen for anemia of CKD)

Common Pitfalls to Avoid

1. Do not stop SGLT2i for a small eGFR dip after initiation—this is expected and protective long-term 1
2. Do not use total body weight for drug dosing calculations in obesity 7
3. Do not withhold RASi when eGFR falls below 30—continue through Stage G4 1
4. Do not rely on creatinine-based eGFR alone in obesity—it underestimates true kidney function and may delay appropriate treatment 2, 8
5. Do not forget to check albuminuria—it is the single most important variable determining medication intensity

Bottom Line

Start SGLT2 inhibitor now. Add RASi if albuminuria ≥30 mg/g or if hypertension/heart failure present. Use combined creatinine-cystatin C eGFR for clinical decisions in obesity. Titrate RASi to maximum tolerated dose. Monitor potassium and creatinine at 2–4 weeks, then quarterly. Continue all agents even as eGFR declines unless specific contraindications arise (hyperkalemia >5.5 despite management, creatinine rise >30% in 4 weeks, symptomatic hypotension, or dialysis initiation).